Akebia Therapeutics, Inc.  Company Profile

06:57 EDT 22nd April 2018 | BioPortfolio

News Articles [723 Associated News Articles listed on BioPortfolio]

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox...

Akebia, Otsuka provide update on changes to vadadustat studies in Japan

Akebia Therapeutics and its Japanese partner Otsuka said design changes have been made to the Phase II and Phase III trials a -More- 

Akebia Announces $85M Public Offering

Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering.

Akebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and Webcast

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox...

Akebia Therapeutics to Present at Upcoming February Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox...

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ... Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

Akebia nets $85mm through public offering

Akebia Therapeutics Inc. netted $85mm through a public offering of 8.5mm common shares at $10.50. The company is developing hypoxia-inducible factor (HIF)-based therapies for kidney disease and associ...

Follow-on sale of shares raises $89.3M for Akebia

The sale of 8.5 million shares in a follow-on brought in $89.3 million for Akebia Therapeutics.  -More- 

PubMed Articles [417 Associated PubMed Articles listed on BioPortfolio]

Akebia quinata Decaisne aqueous extract acts as a novel anti fatigue agent in mice exposed to chronic restraint stress.

Akebia quinata Decaisne extract (AQE) (Lardizabalaceae) is used in traditional herbal medicine for stress-fatigue-related depression, improved fatigue, and mental relaxation.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Introduction to Volume 2 of JOPT Special Issue.

Clinical Trials [139 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1214 Associated Companies listed on BioPortfolio]

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydrox...

Akebia Therapeutics, Inc. 

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Akebia Therapeutics, Inc. " on BioPortfolio

We have published hundreds of Akebia Therapeutics, Inc.  news stories on BioPortfolio along with dozens of Akebia Therapeutics, Inc.  Clinical Trials and PubMed Articles about Akebia Therapeutics, Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Akebia Therapeutics, Inc.  Companies in our database. You can also find out about relevant Akebia Therapeutics, Inc.  Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record